{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:04:55Z","timestamp":1768737895918,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40259-020-00458-3","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T14:27:53Z","timestamp":1607610473000},"page":"35-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-7223","authenticated-orcid":false,"given":"Rodrigo","family":"Borrega","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-6091","authenticated-orcid":false,"given":"Carlos","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"N\u00e1dia","family":"Aguiam","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-3671","authenticated-orcid":false,"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-344X","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lopes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1245-3715","authenticated-orcid":false,"given":"Joao","family":"Goncalves","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"458_CR1","unstructured":"Humira Summary of Product Characteristics. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf. Accessed June 2018."},{"key":"458_CR2","first-page":"608","volume":"73","author":"M Jani","year":"2014","unstructured":"Jani M, Chinoy H, Warren RB, et al. Influence of immunogenicity and drug levels of the efficacy of long-term treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A UK- based prospective study [abstract]. Ann Rheum Dis. 2014;73:608.","journal-title":"Ann Rheum Dis."},{"key":"458_CR3","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition epidemiology and management. ClinTranslGastroenterol. 2016;7:e135. https:\/\/doi.org\/10.1038\/ctg.2015.63.","journal-title":"ClinTranslGastroenterol."},{"key":"458_CR4","first-page":"657","volume":"11","author":"SR Dalal","year":"2015","unstructured":"Dalal SR, Cohen RD. What to do when biologic agents are not working in inflammatory Bowel disease patients. Gastroenterol Hepatol. 2015;11:657\u201365.","journal-title":"GastroenterolHepatol."},{"key":"458_CR5","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Burmester GR, Combe B, et al. Head-to-head comparison of certolizumabpegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388:2763\u201374.","journal-title":"Lancet"},{"key":"458_CR6","first-page":"1429","volume":"32","author":"CC Mok","year":"2013","unstructured":"Mok CC, Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. ClinRheumatol. 2013;32:1429\u201335.","journal-title":"ClinRheumatol."},{"key":"458_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.intimp.2014.04.006","volume":"21","author":"SM Jung","year":"2014","unstructured":"Jung SM, Kim HS, Kim HR, et al. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. IntImmunopharmacol. 2014;21:20\u20135.","journal-title":"IntImmunopharmacol."},{"key":"458_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jbspin.2015.04.020","volume":"83","author":"A Hoxha","year":"2016","unstructured":"Hoxha A, Calligaro A, Tonello M, et al. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicenter study. Jt Bone Spine. 2016;83:167\u201371.","journal-title":"Jt Bone Spine."},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","volume":"28","author":"RL West","year":"2008","unstructured":"West RL, Zelinkova Z, Wolbink JG, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease. Aliment PharmacolTher. 2008;28:1122\u20136.","journal-title":"Aliment PharmacolTher."},{"key":"458_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","volume":"72","author":"PA Schouwenburg","year":"2013","unstructured":"Schouwenburg PA, Stadt LA, Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Ann Rheum Dis. 2013;72:104\u20139.","journal-title":"Ann Rheum Dis."},{"key":"458_CR11","first-page":"431","volume":"4","author":"L Aarden","year":"2008","unstructured":"Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. CurrOpinImmunol. 2008;4:431\u20135.","journal-title":"CurrOpinImmunol."},{"key":"458_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jim.2015.01.007","volume":"418","author":"K Bloem","year":"2015","unstructured":"Bloem K, Leeuwen A, Verbeek G, et al. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods. 2015;418:29\u201338.","journal-title":"J Immunol Methods."},{"key":"458_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00535-013-0803-4","volume":"49","author":"H Imaeda","year":"2014","unstructured":"Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u00b4s disease. J Gastroenterol. 2014;49:100\u20139.","journal-title":"J Gastroenterol."},{"key":"458_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","volume":"40","author":"Y Mazor","year":"2014","unstructured":"Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease. Aliment PharmacolTher. 2014;40:620\u20138.","journal-title":"Aliment PharmacolTher."},{"key":"458_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","volume":"74","author":"GR Burmester","year":"2015","unstructured":"Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomized concerto trial. Ann Rheum Dis. 2015;74:1037\u201344.","journal-title":"Ann Rheum Dis."},{"key":"458_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/s10165-008-0045-0","volume":"18","author":"N Miyasaka","year":"2008","unstructured":"Miyasaka N, Taneichi K, Atsumi T, et al. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252\u201362.","journal-title":"Mod Rheumatol."},{"key":"458_CR17","doi-asserted-by":"publisher","first-page":"e0162316","DOI":"10.1371\/journal.pone.0162316","volume":"11","author":"GP Eng","year":"2016","unstructured":"Eng GP, Bouchelouche P, Bartel EM, et al. Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with Adalimumab or infliximab: a descriptive cohort study. PLoS ONE. 2016;11:e0162316. https:\/\/doi.org\/10.1371\/journal.pone.0162316.","journal-title":"PLoS ONE"},{"key":"458_CR18","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"TRDJ Radstake","year":"2009","unstructured":"Radstake TRDJ, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug. Ann Rheum Dis. 2009;68:1739\u201345.","journal-title":"Ann Rheum Dis."},{"key":"458_CR19","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1002\/art.34680","volume":"64","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Jamnitski A, Nurmohamed MT, et al. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 2012;64:3850\u20135.","journal-title":"Arthritis Rheum."},{"key":"458_CR20","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947\u201355.","journal-title":"Ann Rheum Dis."},{"key":"458_CR21","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","volume":"173","author":"JR Maneiro","year":"2013","unstructured":"Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions systematic review and meta-analysis. JAMA Intern Med. 2013;173:1416\u201328.","journal-title":"JAMA Intern Med."},{"key":"458_CR22","unstructured":"EMEA\/CHMP\/BMWP\/14327\/2006. Guideline on immunogenicity assessment of therapeutic proteins. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed Aug 2019."},{"key":"458_CR23","unstructured":"Food and Drug Administration. Guidance for industry: immunogenicity assessment for therapeutic protein products. 2014. https:\/\/www.fda.gov\/media\/85017\/download. Accessed Oct 2020."},{"key":"458_CR24","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"458_CR25","unstructured":"EMEA\/CHMP\/BMWP\/42832\/2005. Rev1\u2014guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed Aug 2019."},{"key":"458_CR26","unstructured":"Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. 2015. https:\/\/www.fda.gov\/media\/82647\/download. Accessed Oct 2020."},{"key":"458_CR27","first-page":"348","volume":"192","author":"B Gorovits","year":"2018","unstructured":"Gorovits B, Baltrukonis DJ, Bhattacharya I, et al. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. ClinExpImmunol. 2018;192:348\u201365.","journal-title":"ClinExpImmunol."},{"key":"458_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jim.2011.07.019","volume":"372","author":"MH Hart","year":"2011","unstructured":"Hart MH, Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011;372:196\u2013203.","journal-title":"J Immunol Methods."},{"key":"458_CR29","unstructured":"EMEA\/CHMP\/BMWP\/101695\/2006. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. European Medicinas Agency. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-comparability-biotechnology-derived-medicinal-products-after-change-manufacturing-process_en.pdf. Accessed Oct 2020."},{"key":"458_CR30","unstructured":"Food and Drug Administration. Guidance for industry: Q5E comparability of biotechnological\/biological products subject to changes in their manufacturing process. 2005. https:\/\/www.fda.gov\/media\/71489\/download. Accessed Oct 2020."},{"key":"458_CR31","first-page":"1","volume":"1","author":"PM Rothwell","year":"2006","unstructured":"Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoSClin Trials. 2006;1:1\u20135.","journal-title":"PLoSClin Trials."},{"key":"458_CR32","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460\u20138.","journal-title":"JAMA"},{"key":"458_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apt.13862","volume":"45","author":"B Ungar","year":"2017","unstructured":"Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment PharmacolTher. 2017;45:276\u201382.","journal-title":"Aliment PharmacolTher."},{"key":"458_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology. 2004;126:402\u201313.","journal-title":"Gastroenterology"},{"key":"458_CR35","first-page":"542","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. ClinGastroenterolHepatol. 2004;2:542\u201353.","journal-title":"ClinGastroenterolHepatol."},{"key":"458_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-019-00355-4","volume":"33","author":"S Bellinvia","year":"2019","unstructured":"Bellinvia S, Cummings JRF, Ardern-Jones MR, et al. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33:241\u201353.","journal-title":"BioDrugs."},{"key":"458_CR37","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605\u201312.","journal-title":"Ann Rheum Dis."},{"key":"458_CR38","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613\u201320.","journal-title":"Ann Rheum Dis."},{"key":"458_CR39","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/annrheumdis-2013-203296","volume":"73","author":"S Garc\u00eas","year":"2014","unstructured":"Garc\u00eas S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2014;73:1138\u201343.","journal-title":"Ann Rheum Dis."},{"key":"458_CR40","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/gutjnl-2014-307882","volume":"65","author":"F Baert","year":"2016","unstructured":"Baert F, Kondragunta V, Lockton S, et al. Antibodies to adalimumab are associated with future inflammation in Crohn\u2019s patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2016;65:1126\u201331.","journal-title":"Gut"},{"key":"458_CR41","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","volume":"71","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914\u20135.","journal-title":"Ann Rheum Dis."},{"key":"458_CR42","first-page":"2011","volume":"67","author":"M Jani","year":"2015","unstructured":"Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. ArthritisRheumatol. 2015;67:2011\u20139.","journal-title":"ArthritisRheumatol."},{"key":"458_CR43","first-page":"385","volume":"181","author":"B Rup","year":"2015","unstructured":"Rup B, Pallardy M, Sikkema D, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. ClinExpImmunol. 2015;181:385\u2013400.","journal-title":"ClinExpImmunol."},{"key":"458_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16:658\u201373.","journal-title":"AAPS J."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-020-00458-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00458-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T12:37:14Z","timestamp":1610541434000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-020-00458-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00458-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]},"assertion":[{"value":"10 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to support the execution and writing of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JG has received speaker honoraria and consulting fees from Amgen, Biogen, Novartis, Sanofi, Mylan, and Samsung Bioepis. JEF has received unrestricted research grants or acted as a speaker for Abbvie, Ache, Amgen, BIAL, Biogen, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, and UCBF. FM has served as a speaker and received honoraria from Merck Sharp & Dohme, Abbvie, Vifor, Falk, Laborat\u00f3rios Vit\u00f3ria, Ferring, Hospira, and Biogen. SD has served as a speaker, a consultant, and an advisory board member for Schering-Plough, Abbott Laboratories, Merck & Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor, and Johnson and Johnson. RB, CA, NA, and JL have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conception and design of the study: RB, SD, JG. Acquisition of data: RB, CA. Interpretation and analysis of data: RB, CA, NA, JL, JG. Drafting the article or revising it critically for important intellectual content the article: all authors. Final approval of the version to be published: all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}